- Previous Close
1.4600 - Open
1.4600 - Bid 1.3500 x --
- Ask 1.4000 x --
- Day's Range
1.3200 - 1.5100 - 52 Week Range
1.1800 - 1.8800 - Volume
39,391 - Avg. Volume
16,483 - Market Cap (intraday)
33.13M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date Mar 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.90
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
herantis.comRecent News: HRTIS.HE
View MorePerformance Overview: HRTIS.HE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Helsinki_PI (^OMXHPI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HRTIS.HE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HRTIS.HE
View MoreValuation Measures
Market Cap
33.13M
Enterprise Value
31.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
16.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.44%
Return on Equity (ttm)
-220.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.94M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
2.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.72M